In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

GLP-1 Drug Development: Leveraging Integrated Solutions to Improve Patient Engagement
Webinars, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Market Insights, Product Solutions

USP <382>: A Shift in Injectable Packaging Requirements
Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

EU GMP Annex 1: New Standards for Injectable Drug Manufacturing
Webinars, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Market Insights, Product Solutions

Optimizing Autoinjector Performance for Drug Development
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions